Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 8/20 | 0.70 |
| ▸ | FOLR1 | P15328 | 7/20 | 0.70 |
| ▸ | SLC46A1 | Q96NT5 | 7/20 | 0.70 |
| ▸ | TYMS | P04818 | 6/20 | 0.70 |
| ▸ | SLC19A1 | P41440 | 6/20 | 0.70 |
| ▸ | DHFR | P00374 | 5/20 | 0.70 |
| ▸ | FOLR2 | P14207 | 3/20 | 0.70 |
| ▸ | ATIC | P31939 | 2/20 | 0.70 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.70 |
| ▸ | FRK | P42685 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15145417 | 0.93 | GART (0.72) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL15161027 | 0.93 | GART (0.74) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL11990735 | 0.92 | GART (0.69) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL19933020 | 0.92 | GART (0.70) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL15161119 | 0.91 | GART (0.72) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL464402 | 0.91 | GART (0.71) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL21706294 | 0.90 | GART (0.67) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL15078817 | 0.86 | GART (0.84) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL15161026 | 0.85 | GART (0.84) | GARTFOLR1SLC46A1TYMSSLC19A1 | |
| SCHEMBL15078818 | 0.84 | TYMS (0.72) | GARTFOLR1SLC46A1TYMSSLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | GART 2325/4885FOLR1 347/4885SLC46A1 612/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | GART 1740/4885FOLR1 763/4885SLC46A1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.